Prime Medicine Inc (PRME)

Currency in USD
2.920
+0.110(+3.91%)
Real-time Data·
PRME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.8202.960
52 wk Range
2.6706.940
Key Statistics
Prev. Close
2.81
Open
2.85
Day's Range
2.82-2.96
52 wk Range
2.67-6.94
Volume
2.08M
Average Volume (3m)
3.33M
1-Year Change
-35.2222%
Book Value / Share
0.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.117
Upside
+143.73%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Prime Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.117
(+143.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy8.00+174.91%-MaintainJul 10, 2026
TD Cowen
Buy---MaintainJul 08, 2026
H.C. Wainwright
Buy8.00+174.91%-UpgradeJun 29, 2026
Citizens
Buy6.00+106.19%-MaintainJun 22, 2026
Jones Trading
Buy5.00+71.82%-New CoverageApr 06, 2026

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-0.28 / -0.36
Revenue / Forecast
856K / --
EPS Revisions
Last 90 days

PRME Income Statement

Compare PRME to Peers and Sector

Metrics to compare
PRME
Peers
Sector
Relationship
P/E Ratio
−2.7x−1.3x−0.4x
PEG Ratio
−0.11−0.050.00
Price/Book
6.9x1.8x2.6x
Price / LTM Sales
130.5x121.6x3.0x
Upside (Analyst Target)
165.5%184.0%54.3%
Fair Value Upside
Unlock21.2%8.4%Unlock

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
38.71M21.43%108.78M
Other Institutional Investors
115.20M63.78%323.72M
Public Companies & Retail Investors
26.70M14.78%75.03M
Total
180.62M100.00%507.53M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
GV Management Company, LLC9.17%16,562,49846,541
Arch Venture Partners, L.P.6.79%12,256,59434,441

People Also Watch

12.09
REPL
+1.52%
1.555
CRBU
+3.67%
12.94
CLPT
-15.90%
56.530
LDOF
+3.33%
1.940
AUTL
+6.59%

FAQ

What Is the Prime Medicine (PRME) Stock Price Today?

The Prime Medicine stock price today is 2.920 USD.

What Stock Exchange Does Prime Medicine Trade On?

Prime Medicine is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Prime Medicine?

The stock symbol for Prime Medicine is "PRME."

What Is the Prime Medicine Market Cap?

As of today, Prime Medicine market cap is 507.540M USD.

What Is Prime Medicine's Earnings Per Share (TTM)?

The Prime Medicine EPS (TTM) is -1.237.

When Is the Next Prime Medicine Earnings Date?

Prime Medicine will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is PRME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Prime Medicine Stock Split?

Prime Medicine has split 0 times.

How Many Employees Does Prime Medicine Have?

Prime Medicine has 146 employees.

What is the current trading status of Prime Medicine (PRME)?

As of Aug 04, 2026, Prime Medicine (PRME) is trading at a price of 2.920 USD, with a previous close of 2.810 USD. The stock has fluctuated within a day range of 2.820 USD to 2.960 USD, while its 52-week range spans from 2.670 USD to 6.940 USD.

What Is Prime Medicine (PRME) Price Target According to Analysts?

The average 12-month price target for Prime Medicine is 7.117 USD, with a high estimate of 11 USD and a low estimate of 4.25 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +143.73% Upside potential.

What Is the PRME Premarket Price?

PRME's last pre-market stock price is 2.860 USD. The pre-market share volume is 12,800.000, and the stock has decreased by 0.050, or 1.780%.

What Is the PRME After Hours Price?

PRME's last after hours stock price is 2.830 USD, the stock has decreased by 0.020, or 0.710%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.